CPT® Code 80325

Official Description

Amphetamines; 3 or 4

Common Language Description

The CPT® Code 80325 refers to a laboratory test specifically designed to measure the presence of amphetamines in various biological specimens, including serum, urine, saliva, hair, and stool. Amphetamines are a class of central nervous system stimulants that are primarily utilized in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. This code encompasses the testing for three or four different types of amphetamines, which may include both prescription medications and illicit substances. Notably, the category of amphetamines also includes designer drugs such as methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA, commonly known as Ecstasy), and methylenedioxyethylamphetamine (MDEA, referred to as Eve), which possess both stimulant and hallucinogenic properties. Due to their potential for addiction and high rates of abuse, the measurement of amphetamines is critical in various clinical and forensic settings. The detection windows for these substances vary by specimen type: they can be identified in blood or serum for up to 12 hours post-ingestion, in urine for 2 to 5 days, in saliva for 1 to 5 days, and in hair for as long as 90 days. The testing methodologies employed include high-performance liquid chromatography coupled with tandem mass spectrometry for serum, urine, and stool samples, while hair samples are analyzed using gas chromatography/mass spectrometry. Saliva testing is conducted through a rapid immunochromatographic assay. It is important to note that CPT® Code 80324 is designated for testing one or two amphetamines, while CPT® Code 80326 is applicable for testing five or more amphetamines.

1. Indications

The laboratory test represented by CPT® Code 80325 is indicated for the detection and quantification of amphetamines in various biological specimens. This test is typically performed in the following scenarios:

Assessment of Substance Abuse: The test is utilized to evaluate individuals suspected of amphetamine abuse, including both prescription medications and illicit drugs.
Monitoring Treatment Compliance: It is used to ensure that patients prescribed amphetamines for ADHD or narcolepsy are adhering to their treatment regimen.
Forensic Analysis: The test may be employed in legal or forensic contexts to determine the presence of amphetamines in individuals involved in legal cases or accidents.
Clinical Evaluation: Physicians may order this test to investigate symptoms related to amphetamine use or to rule out substance-related disorders.

2. Procedure

The procedure for conducting the laboratory test under CPT® Code 80325 involves several key steps, which are detailed as follows:

Specimen Collection: A biological specimen is collected from the patient, which may include serum, urine, saliva, hair, or stool. The choice of specimen type depends on the clinical context and the specific substances being tested.
Preparation of Specimen: The collected specimen is prepared for analysis. This may involve processes such as centrifugation for serum or urine samples to separate components, or appropriate handling and storage of hair or saliva samples to preserve integrity.
Analytical Testing: The prepared specimen undergoes analytical testing using specific methodologies. Serum, urine, and stool samples are analyzed using high-performance liquid chromatography coupled with tandem mass spectrometry, which allows for precise identification and quantification of amphetamines. Hair samples are tested using gas chromatography/mass spectrometry, while saliva samples are evaluated through a rapid immunochromatographic assay.
Result Interpretation: After the analysis is complete, the results are interpreted by qualified laboratory personnel. The presence and concentration of amphetamines are reported, which can assist healthcare providers in making informed clinical decisions.

3. Post-Procedure

Post-procedure care for patients undergoing testing with CPT® Code 80325 typically involves providing the patient with information regarding the test results and any necessary follow-up actions. Depending on the results, healthcare providers may discuss treatment options, potential referrals for substance abuse counseling, or adjustments to current medications. It is also important to ensure that patients understand the implications of positive test results, particularly in contexts related to legal or employment situations. Additionally, healthcare providers may recommend further testing or monitoring based on the findings of the initial test.

Short Descr	AMPHETAMINES 3OR 4
Medium Descr	DRUG SCREEN QUANT AMPHETAMINES 3 OR 4
Long Descr	Amphetamines; 3 or 4
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1